Safety Data Sheet
acc. to OSHA HCS

Printing date 07/20/2020 Revision date 07/20/2020

*

1 Identification

· **Product identifier**

· **Trade name: IgA1 and IgA2 (human) Monoclonal Antibody**
· **Synonym** Immunoglobulin A1 and A2

· **Article number:** 32114
· **Application of the substance** For research use only - not for human or veterinary use.

· **Details of the supplier of the safety data sheet**
· **Manufacturer/Supplier:**
Cayman Chemical Co.
1180 E. Ellsworth Rd.
Ann Arbor, MI 48108
USA

· **Information department:** Product safety department
· **Emergency telephone number:**
During normal opening times: +1 (734) 971-3335
US/CANADA: 800-424-9300
Outside US/CANADA: 703-741-5970

2 Hazard(s) identification

· **Classification of the substance or mixture**
The product is not classified, according to the Globally Harmonized System (GHS).

· **Label elements**
· **GHS label elements** None
· **Hazard pictograms** None
· **Signal word** None
· **Hazard statements** None
· **Classification system:**
· **NFPA ratings (scale 0 - 4)**

Health = 0
Fire = 1
Reactivity = 0

· **HMIS-ratings (scale 0 - 4)**

Health = 0
Fire = 1
Reactivity = 0

· **Other hazards**
· **Results of PBT and vPvB assessment**
· **PBT:** Not applicable.
· **vPvB:** Not applicable.

(Contd. on page 2)

Safety Data Sheet
acc. to OSHA HCS

Printing date 07/20/2020 Revision date 07/20/2020

Trade name: IgA1 and IgA2 (human) Monoclonal Antibody

(Contd. from page 1)

*
3 Composition/information on ingredients

· **Chemical characterization: Mixtures**
· **Description:** Mixture of the substances listed below with nonhazardous additions.

· **Dangerous components:**		
CAS: 56-81-5 RTECS: MA8050000	Glycerol	50.0%
CAS: 9048-46-8 RTECS: MT6446000	Albumin, bovine	1.0%

· **Other ingredients**		
CAS: 7732-18-5 RTECS: ZC0110000	Water	47.914%
CAS: 7647-14-5 RTECS: VZ4725000	Sodium chloride	0.85%
CAS: 7558-79-4 RTECS: WC4500000	Sodium phosphate, Dibasic	0.106%
CAS: 26628-22-8 RTECS: VY8050000	Sodium azide	0.09%
CAS: 7778-77-0 RTECS: TC6615500	Potassium phosphate, Monobasic	0.03%
	IgA1 and IgA2 (human) Monoclonal Antibody	0.01%

4 First-aid measures

· **Description of first aid measures**
· **General information:** No special measures required.
· **After inhalation:** Supply fresh air; consult doctor in case of complaints.
· **After skin contact:** Generally the product does not irritate the skin.
· **After eye contact:** Rinse opened eye for several minutes under running water.
· **After swallowing:** If symptoms persist consult doctor.
· **Information for doctor:**
· **Most important symptoms and effects, both acute and delayed**
May cause anemia, cough, CNS depression, drowsiness, headache, heart damage, lassitude (weakness, exhaustion), liver damage, narcosis, reproductive effects, teratogenic effects.
No further relevant information available.
· **Indication of any immediate medical attention and special treatment needed**
No further relevant information available.

5 Fire-fighting measures

· **Extinguishing media**
· **Suitable extinguishing agents:**
Use fire fighting measures that suit the environment.
A solid water stream may be inefficient.
· **Special hazards arising from the substance or mixture** No further relevant information available.
· **Advice for firefighters**
· **Protective equipment:** No special measures required.

(Contd. on page 3)

Safety Data Sheet
acc. to OSHA HCS

Printing date 07/20/2020 Revision date 07/20/2020

Trade name: IgA1 and IgA2 (human) Monoclonal Antibody

(Contd. from page 2)

*
6 Accidental release measures

· **Personal precautions, protective equipment and emergency procedures** Not required.
· **Environmental precautions:**
Dilute with plenty of water.
Do not allow to enter sewers/ surface or ground water.
· **Methods and material for containment and cleaning up:**
Absorb with liquid-binding material (sand, diatomite, acid binders, universal binders, sawdust).
· **Reference to other sections**
See Section 7 for information on safe handling.
See Section 8 for information on personal protection equipment.
See Section 13 for disposal information.
· **Protective Action Criteria for Chemicals**

· **PAC-1:**		
56-81-5	Glycerol	45 mg/m³
26628-22-8	Sodium azide	0.026 mg/m³
7778-77-0	Potassium phosphate, Monobasic	9.6 mg/m³

· **PAC-2:**		
56-81-5	Glycerol	180 mg/m³
26628-22-8	Sodium azide	0.29 mg/m³
7778-77-0	Potassium phosphate, Monobasic	110 mg/m³

· **PAC-3:**		
56-81-5	Glycerol	1,100 mg/m³
26628-22-8	Sodium azide	5.3 mg/m³
7778-77-0	Potassium phosphate, Monobasic	630 mg/m³

7 Handling and storage

· **Handling:**
· **Precautions for safe handling** No special measures required.
· **Information about protection against explosions and fires:** No special measures required.

· **Conditions for safe storage, including any incompatibilities**
Keep container tightly closed.
Store in accordance with information listed on the product insert.
· **Storage:**
· **Requirements to be met by storerooms and receptacles:** No special requirements.
· **Information about storage in one common storage facility:** Not required.
· **Further information about storage conditions:** None.
· **Specific end use(s)** No further relevant information available.

*
8 Exposure controls/personal protection

· **Additional information about design of technical systems:** No further data; see item 7.

(Contd. on page 4)

Safety Data Sheet
acc. to OSHA HCS

Printing date 07/20/2020 Revision date 07/20/2020

Trade name: IgA1 and IgA2 (human) Monoclonal Antibody

(Contd. from page 3)

· **Control parameters**

· **Components with limit values that require monitoring at the workplace:**	
56-81-5 Glycerol	
PEL	Long-term value: 15* 5** mg/m³ mist; *total dust **respirable fraction
TLV	TLV withdrawn-insufficient data human occup. exp.

· **Additional information:** The lists that were valid during the creation were used as basis.

· **Exposure controls**
· **Personal protective equipment:**
· **General protective and hygienic measures:**
The usual precautionary measures for handling chemicals should be followed.
· **Breathing equipment:** Not required.
· **Protection of hands:**
The glove material has to be impermeable and resistant to the product/ the substance/ the preparation.
Due to missing tests no recommendation to the glove material can be given for the product/ the preparation/ the chemical mixture.
Selection of the glove material on consideration of the penetration times, rates of diffusion and the degradation
· **Material of gloves**
The selection of the suitable gloves does not only depend on the material, but also on further marks of quality and varies from manufacturer to manufacturer. As the product is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application.
· **Penetration time of glove material**
The exact break through time has to be found out by the manufacturer of the protective gloves and has to be observed.
· **Eye protection:** Goggles recommended during refilling.

*
9 Physical and chemical properties

· **Information on basic physical and chemical properties**	
· **General Information**	
· **Appearance:**	
Form:	Fluid
Color:	According to product specification
· **Odor:**	Characteristic
· **Storage Buffer**	PBS with 50% glycerol, 1% BSA, and 0.09% sodium azide
· **Odor threshold:**	Not determined.
· **Formulation**	100 µg of protein A-purified monoclonal antibody
· **pH-value:**	Not determined.
· **Change in condition**	
Melting point/Melting range:	Undetermined.
Boiling point/Boiling range:	100 °C (212 °F)
· **Flash point:**	199 °C (390.2 °F)
· **Flammability (solid, gaseous):**	Not applicable.
· **Decomposition temperature:**	Not determined.

(Contd. on page 5)

Safety Data Sheet
acc. to OSHA HCS

Printing date 07/20/2020 Revision date 07/20/2020

Trade name: IgA1 and IgA2 (human) Monoclonal Antibody

(Contd. from page 4)

· **Auto igniting:**	Product is not selfigniting.
· **Danger of explosion:**	Product does not present an explosion hazard.
· **Explosion limits:**	
Lower:	Not determined.
Upper:	Not determined.
· **Vapor pressure at 20 °C (68 °F):**	23 hPa (17.3 mm Hg)
· **Density at 20 °C (68 °F):**	0.99795–1.00205 g/cm³ (8.32789–8.36211 lbs/gal)
· **Bulk density:**	998–1,002 kg/m³
· **Relative density**	Not determined.
· **Vapor density**	Not determined.
· **Evaporation rate**	Not determined.
· **Solubility in / Miscibility with**	
Water:	Fully miscible.
· **Partition coefficient (n-octanol/water):**	Not determined.
· **Viscosity:**	
Dynamic:	Not determined.
Kinematic:	Not determined.
· **Solvent content:**	
Organic solvents:	50.0 %
Water:	47.9 %
VOC content:	0.00 % 0.0 g/l / 0.00 lb/gal
Solids content:	1.1 %
· **Other information**	No further relevant information available.

*
10 Stability and reactivity

· **Reactivity** No further relevant information available.
· **Chemical stability**
· **Thermal decomposition / conditions to be avoided:**
No decomposition if used according to specifications.
· **Possibility of hazardous reactions** No dangerous reactions known.
· **Conditions to avoid** No further relevant information available.
· **Incompatible materials:** No further relevant information available.
· **Hazardous decomposition products:** No dangerous decomposition products known.

*
11 Toxicological information

· **Information on toxicological effects**
· **Acute toxicity:**

· **LD/LC50 values that are relevant for classification:**		
ATE (Acute Toxicity Estimate)		
Oral	LD50	50,000 mg/kg

(Contd. on page 6)

Safety Data Sheet
acc. to OSHA HCS

Printing date 07/20/2020 Revision date 07/20/2020

Trade name: IgA1 and IgA2 (human) Monoclonal Antibody

(Contd. from page 5)

56-81-5 Glycerol		
Oral	LD50	12,600 mg/kg (rat)
Irritation of skin	Irritation	500 mg/24h (rabbit)
Irritation of eyes	Irritation	500 mg/24h (rabbit)
	Intraperitoneal LD50	4,420 mg/kg (rat)
	Subcutaneous LD50	100 mg/kg (rat)
9048-46-8 Albumin, bovine		
	Intraperitoneal TDLO	0.2 pph (mouse)
26628-22-8 Sodium azide		
Oral	LDLO	27 mg/kg (rat)
	TDLO	3 ml/kg (wmn)
	LD50	27 mg/kg (rat)
	Subcutaneous LD50	45,100 µg/kg (rat)
Dermal	LD50	50 mg/kg (rat)
		20 mg/kg (rabbit)
Inhalative	LC50	37 mg/m³ (rat)
	Subcutaneous LD50	45,100 µg/kg (rat)
	Interperitoneal LDLO	30 mg/kg (rat)
	Intraperitoneal LD50	28 mg/kg (mouse)
	Subcutaneous LD50	45 mg/kg (rat)
	Data	5,500 mg/kg (mouse)

· **Primary irritant effect:**
· **on the skin:** No irritant effect.
· **on the eye:** No irritating effect.
· **Sensitization:** No sensitizing effects known.
· **Additional toxicological information:**
The product is not subject to classification according to internally approved calculation methods for preparations:
When used and handled according to specifications, the product does not have any harmful effects according to our experience and the information provided to us.

· **Carcinogenic categories**

· **IARC (International Agency for Research on Cancer)**
None of the ingredients is listed.

· **NTP (National Toxicology Program)**
None of the ingredients is listed.

· **OSHA-Ca (Occupational Safety & Health Administration)**
None of the ingredients is listed.

12 Ecological information

· **Toxicity**
· **Aquatic toxicity:** No further relevant information available.
· **Persistence and degradability** No further relevant information available.
· **Behavior in environmental systems:**
· **Bioaccumulative potential** No further relevant information available.
· **Mobility in soil** No further relevant information available.

(Contd. on page 7)

Safety Data Sheet
acc. to OSHA HCS

Printing date 07/20/2020 Revision date 07/20/2020

Trade name: IgA1 and IgA2 (human) Monoclonal Antibody

(Contd. from page 6)

· **Additional ecological information:**
· **General notes:**
Water hazard class 1 (Self-assessment): slightly hazardous for water
Do not allow undiluted product or large quantities of it to reach ground water, water course or sewage system.
· **Results of PBT and vPvB assessment**
· **PBT:** Not applicable.
· **vPvB:** Not applicable.
· **Other adverse effects** No further relevant information available.

13 Disposal considerations

· **Waste treatment methods**
· **Recommendation:** Smaller quantities can be disposed of with household waste.

· **Uncleaned packagings:**
· **Recommendation:** Disposal must be made according to official regulations.
· **Recommended cleansing agent:** Water, if necessary with cleansing agents.

*
14 Transport information

· **UN-Number** · **DOT, IMDG, IATA**	not regulated
· **UN proper shipping name** · **DOT, IMDG, IATA**	not regulated
· **Transport hazard class(es)** · **DOT, ADN, IMDG, IATA** · **Class**	not regulated
· **Packing group** · **DOT, IMDG, IATA**	not regulated
· **Environmental hazards:**	Not applicable.
· **Special precautions for user**	Not applicable.
· **Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code**	Not applicable.
· **UN "Model Regulation":**	not regulated

*
15 Regulatory information

· **Safety, health and environmental regulations/legislation specific for the substance or mixture**
· **Sara**

· **Section 355 (extremely hazardous substances):**	
26628-22-8	Sodium azide

· **Section 313 (Specific toxic chemical listings):**	
26628-22-8	Sodium azide

(Contd. on page 8)

Safety Data Sheet
acc. to OSHA HCS

Printing date 07/20/2020 Revision date 07/20/2020

Trade name: IgA1 and IgA2 (human) Monoclonal Antibody

(Contd. from page 7)

· **TSCA (Toxic Substances Control Act):**

56-81-5	Glycerol	ACTIVE
7732-18-5	Water	ACTIVE
9048-46-8	Albumin, bovine	ACTIVE
7647-14-5	Sodium chloride	ACTIVE
7558-79-4	Sodium phosphate, Dibasic	ACTIVE
26628-22-8	Sodium azide	ACTIVE
7778-77-0	Potassium phosphate, Monobasic	ACTIVE

· **Hazardous Air Pollutants**

None of the ingredients is listed.

· **Proposition 65**

· **Chemicals known to cause cancer:**

None of the ingredients is listed.

· **Chemicals known to cause reproductive toxicity for females:**

None of the ingredients is listed.

· **Chemicals known to cause reproductive toxicity for males:**

None of the ingredients is listed.

· **Chemicals known to cause developmental toxicity:**

None of the ingredients is listed.

· **Carcinogenic categories**

· **EPA (Environmental Protection Agency)**

None of the ingredients is listed.

· **TLV (Threshold Limit Value established by ACGIH)**

26628-22-8	Sodium azide	A4

· **NIOSH-Ca (National Institute for Occupational Safety and Health)**

None of the ingredients is listed.

· **GHS label elements** None
· **Hazard pictograms** None
· **Signal word** None
· **Hazard statements** None
· **Chemical safety assessment:** A Chemical Safety Assessment has not been carried out.

16 Other information

This information is based on our present knowledge. However, this shall not constitute a guarantee for any specific product features and shall not establish a legally valid contractual relationship.

· **Department issuing SDS:** Environment protection department.
· **Contact:** -
· **Date of preparation / last revision** 07/20/2020 / -
· **Abbreviations and acronyms:**
IMDG: International Maritime Code for Dangerous Goods
DOT: US Department of Transportation
IATA: International Air Transport Association
ACGIH: American Conference of Governmental Industrial Hygienists
EINECS: European Inventory of Existing Commercial Chemical Substances
ELINCS: European List of Notified Chemical Substances
CAS: Chemical Abstracts Service (division of the American Chemical Society)
NFPA: National Fire Protection Association (USA)

(Contd. on page 9)

Safety Data Sheet
acc. to OSHA HCS

Printing date 07/20/2020 Revision date 07/20/2020

Trade name: IgA1 and IgA2 (human) Monoclonal Antibody

(Contd. from page 8)

HMIS: Hazardous Materials Identification System (USA)
VOC: Volatile Organic Compounds (USA, EU)
LC50: Lethal concentration, 50 percent
LD50: Lethal dose, 50 percent
PBT: Persistent, Bioaccumulative and Toxic
vPvB: very Persistent and very Bioaccumulative
NIOSH: National Institute for Occupational Safety
OSHA: Occupational Safety & Health
TLV: Threshold Limit Value
PEL: Permissible Exposure Limit
REL: Recommended Exposure Limit

· *** Data compared to the previous version altered.**